The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target.

Published in: Diabetes & vascular disease research (2024)

HMGB-1 and its receptors i.e. receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs) present promising targets for antidiabetic interventions. Ongoing and future projects in this realm hold promise for innovative approaches targeting HMGB-1-mediated inflammation to ameliorate diabetes and its complications.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
risk factors
oxidative stress
binding protein
transcription factor
physical activity
current status
big data
quality improvement
machine learning
adipose tissue
artificial intelligence
drug delivery